Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational, Retrospective, Cohort Study

Abstract

The present study provides the first known comparison of cardiac event risk in patients with MM versus age- and gender-matched patients without MM. The cardiac event risk was greater in MM patients with ≥ 3 previous drugs for any cardiac event, dysrhythmias, congestive heart failure, cardiomyopathy, and conduction disorders compared with patients without MM.

Possibilities of Ivabradine, a Selective Inhibitor of Ion F-Channels of Sinus Node, in Prevention of Anthracycline Cardiotoxicity in Patients With Breast Cancer

“…Антрациклин-индуцированная кардиотоксичность носит кумулятив-ный, дозозависимый характер и приводит к необра-тимому повреждению сердца. Например, кумулятив-ная доза доксорубицина 400 мг/м 2 в 5% случаев со-пряжена с развитием застойной СН, а при назначении высоких доз доксорубицина (700 и более мг/м 2 ) про-исходит экспоненциальное, до 48%, увеличение рис-ка развития хронической сердечной недостаточности (ХСН) [4][5][6][7]. Однако существуют значительные разли-…”

Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)

“…7 Of interest, the incidence of cardiovascular disease has been described to be higher in patients with MM (60.1%) than in non-MM patients (54.5%) 7 and a recent review and meta-analysis of patients enrolled in clinical trials with carfilzomib showed that the incidence of all grade and grades ≥3 cardiovascular adverse events (CVAEs) was 18.1% and 8.2%, respectively. 8 Although carfilzomib is one of the most cardiotoxic and, at the same time, effective novel agents used in MM treatment, it is not the only anti-myeloma drug characterized by a high risk of CVAEs.…”

Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies

“…Multiple myeloma (MM) is a challenging disease to manage with a number of age-and disease-related comorbidities [1][2][3][4]. While renal and bone disease are among the most common comorbidities, patients with MM are also at a higher risk for developing cardiovascular comorbidities due to the interaction of patient-related (e.g.…”

“…While renal and bone disease are among the most common comorbidities, patients with MM are also at a higher risk for developing cardiovascular comorbidities due to the interaction of patient-related (e.g. diabetes, diet, lipid levels, weight), disease-related, and treatment-related risk factors [4]. An observational retrospective cohort study (2006)(2007)(2008)(2009)(2010)(2011) reported a significantly higher prevalence of cardiovascular events in previously treated patients with MM versus those without MM (52% vs 35% p < 0.0001), including elevated rates of arrhythmias, congestive heart failure, cardiomyopathies, and conduction disorders [4].…”